#BEGIN_DRUGCARD DB00817

# AHFS_Codes:
Not Available

# ATC_Codes:
J01MB01

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Eracine
Eradacil
Eradacin
Roxadyl
Winuron

# CAS_Registry_Number:
40034-42-2

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H14N2O3

# Chemical_IUPAC_Name:
1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
0.0209 mg/mL at 25 °C

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Rosoxacin

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)

# InChI_Key:
InChIKey=XBPZXDSZHPDXQU-UHFFFAOYSA-N

# Indication:
For the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02305

# LIMS_Drug_ID:
817

# Mechanism_Of_Action:
Rosoxacin binds to and inhibits the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

# Melting_Point:
290 °C

# Molecular_Weight_Avg:
294.3047

# Molecular_Weight_Mono:
294.100442324

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164776843

# Pharmacology:
Rosoxacin is a nonfluorinated quinolone antibiotic. Its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Rosoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

# Predicted_LogP_Hydrophobicity:
1.85

# Predicted_LogS:
-3.5

# Predicted_Water_Solubility:
1.02e-01 g/l

# Primary_Accession_No:
DB00817

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
287180

# PubChem_Substance_ID:
46508469

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00369

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Acrosoxacin
ROS
Rosoxacine [INN-French]
Rosoxacino [INN-Spanish]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:40 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3010848	Zweerink MM, Edison A: Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601.
3532944	Hirai K, Aoyama H, Suzue S, Irikura T, Iyobe S, Mitsuhashi S: Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother. 1986 Aug;30(2):248-53.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X04341

# Drug_Target_1_GenBank_ID_Protein:
41646

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
gyrB

# Drug_Target_1_Gene_Sequence:
>2415 bp
ATGTCGAATTCTTATGACTCCTCCAGTATCAAAGTCCTGAAAGGGCTGGATGCGGTGCGT
AAGCGCCCGGGTATGTATATCGGCGACACGGATGACGGCACCGGTCTGCACCACATGGTA
TTCGAGGTGGTAGATAACGCTATCGACGAAGCGCTCGCGGGTCACTGTAAAGAAATTATC
GTCACCATTCACGCCGATAACTCTGTCTCTGTACAGGATGACGGGCGCGGCATTCCGACC
GGTATTCACCCGGAAGAGGGCGTATCGGCGGCGGAAGTGATCATGACCGTTCTGCACGCA
GGCGGTAAATTTGACGATAACTCCTATAAAGTGTCCGGCGGTCTGCACGGCGTTGGTGTT
TCGGTAGTAAACGCCCTGTCGCAAAAACTGGAGCTGGTTATCCAGCGCGAGGGTAAAATT
CACCGTCAGATCTACGAACACGGTGTACCGCAGGCCCCGCTGGCGGTTACCGGCGAGACT
GAAAAAACCGGCACCATGGTGCGTTTCTGGCCCAGCCTCGAAACCTTCACCAATGTGACC
GAGTTCGAATATGAAATTCTGGCGAAACGTCTGCGTGAGTTGTCGTTCCTCAACTCCGGC
GTTTCCATTCGTCTGCGCGACAAGCGCGACGGCAAAGAAGACCACTTCCACTATGAAGGC
GGCATCAAGGCGTTCGTTGAATATCTGAACAAGAACAAAACGCCGATCCACCCGAATATC
TTCTACTTCTCCACTGAAAAAGACGGTATTGGCGTCGAAGTGGCGTTGCAGTGGAACGAT
GGCTTCCAGGAAAACATCTACTGCTTTACCAACAACATTCCGCAGCGTGACGGCGGTACT
CACCTGGCAGGCTTCCGTGCGGCGATGACCCGTACCCTGAACGCCTACATGGACAAAGAA
GGCTACAGCAAAAAAGCCAAAGTCAGCGCCACCGGTGACGATGCGCGTGAAGGCCTGATT
GCGGTCGTTTCCGTGAAAGTGCCGGACCCGAAATTCTCCTCCCAGACCAAAGACAAACTG
GTTTCTTCTGAGGTGAAATCGGCGGTTGAACAGCAGATGAACGAACTGCTGGCAGAATAC
CTGCTGGAAAACCCAACCGACGCGAAAATCGTGGTTGGCAAAATTATCGATGCTGCCCGT
GCCCGTGAAGCGGCGCGTCGCGCGCGTGAAATGACCCGCCGTAAAGGTGCGCTCGACTTA
GCGGGCCTGCCGGGCAAACTGGCAGACTGCCAGGAACGCGATCCGGCGCTTTCCGAACTG
TACCTGGTGGAAGGGGACTCCGCGGGCGGCTCTGCGAAGCAGGGGCGTAACCGCAAGAAC
CAGGCGATTCTGCCGCTGAAGGGTAAAATCCTCAACGTCGAGAAAGCGCGCTTCGATAAG
ATGCTCTCTTCTCAGGAAGTGGCGACGCTTATCACCGCGCTTGGCTGTGGTATCGGTCGT
GACGAGTACAACCCGGACAAACTGCGTTATCACAGCATCATCATCATGACCGATGCGGAC
GTCGACGGCTCGCACATTCGTACGCTGCTGTTGACCTTCTTCTATCGTCAGATGCCGGAA
ATCGTTGAACGCGGTCACGTCTATATCGCTCAGCCGCCGCTGTACAAAGTGAAGAAAGGC
AAGCAGGAACAGTACATTAAAGACGACGAAGCGATGGATCAGTACCAGATCTCTATCGCG
CTGGACGGCGCAACGCTGCACACCAACGCCAGTGCACCGGCATTGGCTGGCGAAGCGTTA
GAGAAACTGGTATCTGAGTACAACGCGACGCAGAAAATGATCAATCGTATGGAGCGTCGT
TATCCGAAAGCAATGCTGAAAGAGCTTATCTATCAGCCGACGTTGACGGAAGCTGACCTT
TCTGATGAGCAGACCGTTACCCGCTGGGTGAACGCGCTGGTCAGCGAACTGAACGACAAA
GAACAGCACGGCAGCCAGTGGAAGTTTGATGTTCACACCAATGCTGAGCAAAACCTGTTC
GAGCCGATTGTTCGCGTGCGTACCCACGGTGTGGATACTGACTATCCGCTGGATCACGAG
TTTATCACCGGTGGCGAATATCGTCGTATCTGCACGCTGGGTGAGAAACTGCGTGGCTTG
CTGGAAGAAGATGCGTTTATCGAACGTGGCGAGCGTCGTCAGCCGGTAGCCAGCTTCGAG
CAGGCGCTGGACTGGCTGGTGAAAGAGTCCCGTCGCGGCCTCTCCATCCAGCGTTATAAA
GGTCTGGGCGAGATGAACCCGGAACAGCTGTGGGAAACCACTATGGACCCGGAAAGTCGT
CGTATGCTGCGCGTTACCGTTAAAGATGCGATTGCTGCCGACCAGTTGTTCACCACGCTG
ATGGGCGACGCCGTTGAACCGCGCCGTGCGTTTATTGAAGAGAACGCCCTGAAAGCGGCG
AATATCGATATTTAA

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
1646964	Wigley DB, Davies GJ, Dodson EJ, Maxwell A, Dodson G: Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature. 1991 Jun 20;351(6328):624-9.
1656869	Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S: Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647-50.
1846808	Vizan JL, Hernandez-Chico C, del Castillo I, Moreno F: The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase. EMBO J. 1991 Feb;10(2):467-76.
2174443	Tamura JK, Gellert M: Characterization of the ATP binding site on Escherichia coli DNA gyrase. Affinity labeling of Lys-103 and Lys-110 of the B subunit by pyridoxal 5'-diphospho-5'-adenosine. J Biol Chem. 1990 Dec 5;265(34):21342-9.
3020376	Yamagishi J, Yoshida H, Yamayoshi M, Nakamura S: Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet. 1986 Sep;204(3):367-73.
3029031	Menzel R, Gellert M: Fusions of the Escherichia coli gyrA and gyrB control regions to the galactokinase gene are inducible by coumermycin treatment. J Bacteriol. 1987 Mar;169(3):1272-8.
3029692	Adachi T, Mizuuchi M, Robinson EA, Appella E, O'Dea MH, Gellert M, Mizuuchi K: DNA sequence of the E. coli gyrB gene: application of a new sequencing strategy. Nucleic Acids Res. 1987 Jan 26;15(2):771-84.
6089112	Adachi T, Mizuuchi K, Menzel R, Gellert M: DNA sequence and transcription of the region upstream of the E. coli gyrB gene. Nucleic Acids Res. 1984 Aug 24;12(16):6389-95.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
9148951	Funatsuki K, Tanaka R, Inagaki S, Konno H, Katoh K, Nakamura H: acrB mutation located at carboxyl-terminal region of gyrase B subunit reduces DNA binding of DNA gyrase. J Biol Chem. 1997 May 16;272(20):13302-8.
9245398	Holdgate GA, Tunnicliffe A, Ward WH, Weston SA, Rosenbrock G, Barth PT, Taylor IW, Pauptit RA, Timms D: The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study. Biochemistry. 1997 Aug 12;36(32):9663-73.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
887

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
89820

# Drug_Target_1_Name:
DNA gyrase subunit B

# Drug_Target_1_Number_of_Residues:
803

# Drug_Target_1_PDB_ID:
1EI1

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF01751	Toprim
PF02518	HATPase_c

# Drug_Target_1_Protein_Sequence:
>DNA gyrase subunit B
SNSYDSSSIKVLKGLDAVRKRPGMYIGDTDDGTGLHHMVFEVVDNAIDEALAGHCKEIIV
TIHADNSVSVQDDGRGIPTGIHPEEGVSAAEVIMTVLHAGGKFDDNSYKVSGGLHGVGVS
VVNALSQKLELVIQREGKIHRQIYEHGVPQAPLAVTGETEKTGTMVRFWPSLETFTNVTE
FEYEILAKRLRELSFLNSGVSIRLRDKRDGKEDHFHYEGGIKAFVEYLNKNKTPIHPNIF
YFSTEKDGIGVEVALQWNDGFQENIYCFTNNIPQRDGGTHLAGFRAAMTRTLNAYMDKEG
YSKKAKVSATGDDAREGLIAVVSVKVPDPKFSSQTKDKLVSSEVKSAVEQQMNELLAEYL
LENPTDAKIVVGKIIDAARAREAARRAREMTRRKGALDLAGLPGKLADCQERDPALSELY
LVEGDSAGGSAKQGRNRKNQAILPLKGKILNVEKARFDKMLSSQEVATLITALGCGIGRD
EYNPDKLRYHSIIIMTDADVDGSHIRTLLLTFFYRQMPEIVERGHVYIAQPPLYKVKKGK
QEQYIKDDEAMDQYQISIALDGATLHTNASAPALAGEALEKLVSEYNATQKMINRMERRY
PKAMLKELIYQPTLTEADLSDEQTVTRWVNALVSELNDKEQHGSQWKFDVHTNAEQNLFE
PIVRVRTHGVDTDYPLDHEFITGGEYRRICTLGEKLRGLLEEDAFIERGERRQPVASFEQ
ALDWLVKESRRGLSIQRYKGLGEMNPEQLWETTMDPESRRMLRVTVKDAIAADQLFTTLM
GDAVEPRRAFIEENALKAANIDI

# Drug_Target_1_Reaction:
ATP-dependent breakage, passage and rejoining of double-stranded DNA INHIBITOR Coumermycin A1; GRI22222X; Nalidixic acid; Novobiocin; Ciprofloxacin

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_1_SwissProt_ID:
P0AES6

# Drug_Target_1_SwissProt_Name:
GYRB_ECOLI

# Drug_Target_1_Synonyms:
EC 5.99.1.3

# Drug_Target_1_Theoretical_pI:
5.93

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Bacterial cell membrane
peripheral membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3010848	Zweerink MM, Edison A: Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M58408

# Drug_Target_2_GenBank_ID_Protein:
147106

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
parC

# Drug_Target_2_Gene_Sequence:
>2193 bp
ATGTACGTGATCATGGACCGTGCGTTGCCGTTTATTGGTGATGGTCTGAAACCTGTTCAG
CGCCGCATTGTGTATGCGATGTCTGAACTGGGCCTGAATGCCAGCGCCAAATTTAAAAAA
TCGGCCCGTACCGTCGGTGACGTACTGGGTAAATACCATCCGCACGGCGATAGCGCCTGT
TATGAAGCGATGGTCCTGATGGCGCAACCGTTCTCTTACCGTTATCCGCTGGTTGATGGT
CAGGGGAACTGGGGCGCGCCGGACGATCCGAAATCGTTCGCGGCAATGCGTTACACCGAA
TCCCGGTTGTCGAAATATTCCGAGCTGCTATTGAGCGAGCTGGGGCAGGGGACGGCTGAC
TGGGTGCCAAACTTCGACGGCACTTTGCAGGAGCCGAAAATGCTACCTGCCCGTCTGCCA
AACATTTTGCTTAACGGCACCACCGGTATTGCCGTCGGCATGGCGACCGATATTCCACCG
CATAACCTGCGTGAAGTGGCTCAGGCGGCAATCGCATTAATCGACCAGCCGAAAACCACG
CTCGATCAGCTGCTGGATATCGTGCAGGGGCCGGATTATCCGACTGAAGCGGAAATTATC
ACTTCGCGCGCCGAGATCCGTAAAATCTACGAGAACGGACGTGGTTCAGTGCGTATGCGC
GCGGTGTGGAAGAAAGAAGATGGCGCGGTGGTTATCAGCGCATTGCCGCATCAGGTTTCA
GGTGCGCGCGTACTGGAGCAAATTGCTGCGCAAATGCGCAACAAAAAGCTGCCGATGGTT
GACGATCTGCGCGATGAATCTGACCACGAGAACCCGACCCGCCTGGTGATTGTGCCGCGT
TCCAACCGCGTGGATATGGATCAGGTGATGAACCACCTCTTCGCTACCACCGATCTGGAA
AAGAGCTATCGTATTAACCTTAATATGATCGGTCTGGATGGTCGTCCGGCGGTGAAAAAC
CTGCTGGAAATCCTCTCCGAATGGCTGGTGTTCCGCCGCGATACCGTGCGCCGCCGACTG
AACTATCGTCTGGAGAAAGTCCTCAAGCGCCTGCATATCCTCGAAGGTTTGCTGGTGGCG
TTTCTCAATATCGACGAAGTGATTGAGATCATTCGTAATGAAGATGAACCGAAACCGGCG
CTGATGTCGCGGTTTGGCCTTACGGAAACCCAGGCGGAAGCGATCCTCGAACTGAAACTG
CGTCATCTTGCCAAACTGGAAGAGATGAAGATTCGCGGTGAGCAGAGTGAACTGGAAAAA
GAGCGCGACCAGTTGCAGGGCATTTTGGCTTCCGAGCGTAAAATGAATAACCTGCTGAAG
AAAGAACTGCAGGCAGACGCGCAAGCCTACGGTGACGATCGTCGTTCGCCGTTGCAGGAA
CGCGAAGAAGCGAAAGCGATGAGCGAGCACGACATGCTGCCGTCTGAACCTGTCACCATT
GTGCTGTCGCAGATGGGCTGGGTACGCAGCGCTAAAGGCCATGATATCGACGCGCCGGGC
CTGAATTATAAAGCGGGTGATAGCTTCAAAGCGGCGGTGAAAGGTAAGAGCAACCAACCG
GTAGTGTTTGTTGATTCCACCGGTCGTAGCTATGCCATTGACCCGATTACGCTGCCGTCG
GCGCGTGGTCAGGGCGAGCCGCTCACCGGCAAATTAACGTTGCCGCCTGGGGCGACCGTT
GACCATATGCTGATGGAAAGCGACGATCAGAAACTGCTGATGGCTTCCGATGCGGGTTAC
GGTTTCGTCTGCACCTTTAACGATCTGGTGGCGCGTAACCGTGCAGGTAAGGCTTTGATC
ACCTTACCGGAAAATGCCCATGTTATGCCGCCGGTGGTGATTGAAGATGCTTCCGATATG
CTGCTGGCAATCACTCAGGCAGGCCGTATGTTGATGTTCCCGGTAAGTGATCTGCCGCAG
CTGTCGAAGGGCAAAGGCAACAAGATTATCAACATTCCATCGGCAGAAGCCGCGCGTGGA
GAAGATGGTCTGGCGCAATTGTACGTTCTGCCGCCGCAAAGCACGCTGACCATTCATGTT
GGGAAACGCAAAATTAAACTGCGCCCGGAAGAGTTACAGAAAGTCACTGGCGAACGTGGA
CGCCGCGGTACGTTGATGCGCGGTTTGCAGCGTATCGATCGTGTTGAGATCGACTCTCCT
CGCCGTGCCAGCAGCGGTGATAGCGAAGAGTAA

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
1557036	Coleman J: Characterization of the Escherichia coli gene for 1-acyl-sn-glycerol-3-phosphate acyltransferase (plsC). Mol Gen Genet. 1992 Mar;232(2):295-303.
2170028	Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H: New topoisomerase essential for chromosome segregation in E. coli. Cell. 1990 Oct 19;63(2):393-404.
8227000	Peng H, Marians KJ: Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem. 1993 Nov 15;268(32):24481-90.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
886

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
83833

# Drug_Target_2_Name:
DNA topoisomerase 4 subunit A

# Drug_Target_2_Number_of_Residues:
752

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_2_Protein_Sequence:
>DNA topoisomerase 4 subunit A
MSDMAERLALHEFTENAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMSELGLNASAKF
KKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSFAAMRY
TESRLSKYSELLLSELGQGTADWVPNFDGTLQEPKMLPARLPNILLNGTTGIAVGMATDI
PPHNLREVAQAAIALIDQPKTTLDQLLDIVQGPDYPTEAEIITSRAEIRKIYENGRGSVR
MRAVWKKEDGAVVISALPHQVSGARVLEQIAAQMRNKKLPMVDDLRDESDHENPTRLVIV
PRSNRVDMDQVMNHLFATTDLEKSYRINLNMIGLDGRPAVKNLLEILSEWLVFRRDTVRR
RLNYRLEKVLKRLHILEGLLVAFLNIDEVIEIIRNEDEPKPALMSRFGLTETQAEAILEL
KLRHLAKLEEMKIRGEQSELEKERDQLQGILASERKMNNLLKKELQADAQAYGDDRRSPL
QEREEAKAMSEHDMLPSEPVTIVLSQMGWVRSAKGHDIDAPGLNYKAGDSFKAAVKGKSN
QPVVFVDSTGRSYAIDPITLPSARGQGEPLTGKLTLPPGATVDHMLMESDDQKLLMASDA
GYGFVCTFNDLVARNRAGKALITLPENAHVMPPVVIEDASDMLLAITQAGRMLMFPVSDL
PQLSKGKGNKIINIPSAEAARGEDGLAQLYVLPPQSTLTIHVGKRKIKLRPEELQKVTGE
RGRRGTLMRGLQRIDRVEIDSPRRASSGDSEE

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Topoisomerase IV is essential for chromosome segregation. It has relaxation of supercoiled DNA activity. Performs the decatenation events required during the replication of a circular DNA molecule

# Drug_Target_2_SwissProt_ID:
P0AFI2

# Drug_Target_2_SwissProt_Name:
PARC_ECOLI

# Drug_Target_2_Synonyms:
EC 5.99.1.-
Topoisomerase IV subunit A

# Drug_Target_2_Theoretical_pI:
6.65

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00817
